Capital Fund Management S.A. raised its stake in Abiomed Inc. (NASDAQ:ABMD) by 161.9% during the second quarter, Holdings Channel reports. The institutional investor owned 14,654 shares of the company’s stock after buying an additional 9,059 shares during the period. Capital Fund Management S.A.’s holdings in Abiomed were worth $1,602,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of ABMD. Bessemer Group Inc. raised its position in Abiomed by 94.3% in the first quarter. Bessemer Group Inc. now owns 1,226 shares of the company’s stock valued at $116,000 after buying an additional 595 shares in the last quarter. Affinity Wealth Management purchased a new stake in Abiomed during the first quarter valued at about $200,000. Miles Capital Inc. purchased a new stake in Abiomed during the first quarter valued at about $253,000. LS Investment Advisors LLC increased its stake in Abiomed by 68.4% in the second quarter. LS Investment Advisors LLC now owns 2,615 shares of the company’s stock valued at $286,000 after buying an additional 1,062 shares in the last quarter. Finally, Virginia Retirement System purchased a new stake in Abiomed during the first quarter valued at about $303,000. Hedge funds and other institutional investors own 93.65% of the company’s stock.
Abiomed Inc. (NASDAQ:ABMD) traded down 0.02% during mid-day trading on Friday, hitting $128.47. The company had a trading volume of 352,183 shares. The firm has a market capitalization of $5.50 billion, a PE ratio of 136.67 and a beta of 0.75. Abiomed Inc. has a 12-month low of $67.81 and a 12-month high of $131.16. The company’s 50 day moving average price is $122.72 and its 200-day moving average price is $109.43.
Abiomed (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.06. The business had revenue of $103 million for the quarter, compared to analysts’ expectations of $97.23 million. Abiomed had a net margin of 11.75% and a return on equity of 11.86%. The business’s quarterly revenue was up 40.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.20 earnings per share. On average, analysts forecast that Abiomed Inc. will post $1.17 EPS for the current fiscal year.
Several research firms have issued reports on ABMD. Zacks Investment Research raised Abiomed from a “hold” rating to a “buy” rating and set a $138.00 price target on the stock in a research note on Friday, September 16th. Jefferies Group reissued a “buy” rating and issued a $125.00 price target on shares of Abiomed in a research note on Friday, June 10th. Finally, Leerink Swann reissued an “outperform” rating and issued a $125.00 price target on shares of Abiomed in a research note on Wednesday, September 28th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $116.59.
In other Abiomed news, Director Dorothy E. Puhy sold 3,900 shares of the company’s stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $122.31, for a total transaction of $477,009.00. Following the sale, the director now owns 33,811 shares of the company’s stock, valued at $4,135,423.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael R. Minogue sold 5,034 shares of the company’s stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $127.07, for a total transaction of $639,670.38. Following the sale, the chief executive officer now directly owns 215,782 shares in the company, valued at approximately $27,419,418.74. The disclosure for this sale can be found here. Company insiders own 10.00% of the company’s stock.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abiomed Inc. (NASDAQ:ABMD).
Receive News & Ratings for Abiomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.